The company's portfolio addresses the unmet medical needs of millions of patients with eye diseases, with a focus on dry eye disease (DED). They have two late-stage development compounds, NOV03 and CyclASol®, which have shown superior clinical benefit in treating evaporative DED and aqueous deficient DED, respectively. NovaTears® water-free eye drops for DED have CE certification and are commercialized in Australia/New Zealand and Europe. Novaliq is headquartered in Heidelberg, Germany, with an office in Cambridge, MA, USA, and is backed by dievini Hopp BioTech Holding.